ArticleFrontiers in medicine2025
Towards a clinical pathway to food for special medical purpose in China: current progress based on a cross-sectional survey.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of a high-protein food for special medical purposes in midlife and older adults at risk of malnutrition: a multicenter, randomized, active-controlled clinical study.The journal of nutrition, health & aging · 2026Trial
- Clinical application and institutional governance of foods for special medical purposes in medical institutions of eastern coastal China: a cross-sectional study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: To investigate the current status of clinical pathway implementation for food for special medical purpose (FSMP) in China and provide a scientific basis for constructing a standardized pathway. Methods and study design: An E-questionnaire was distributed to 27 clinical nutrition quality control centers in tertiary medical institutions in China from September to October 2023 via random stratified sampling. Results: Ninety-eight valid questionnaires were ultimately recovered. The number of FSMPs used ranged from 1 to 33. The rates of active nutritional risk screening, nutritional status assessment and diagnosis before FSMP therapy were 93.87, 93.88, and 97.96%, respectively. In addition to nutritional physicians, dietitians, and clinicians, nurses participated in prescribing FSMP in 12.24% of the hospitals. Before a prescription was issued, 65 (66.33%) hospitals had an audit process conducted by superior clinicians or dietitians. The frequency of routine ward rounds for more than half of the hospitalized inpatients was once a day. Post-discharge follow-up was implemented in 57 (58.16%) hospitals. The preparation of FSMP in 77 (87.50%) hospitals was included in the supervision of nosocomial infection. The frequency of infection supervision in half of the hospitals was once a month. Sixty-four (65.31%) hospitals had established monitoring and treatment plans for FSMP adverse reactions. Eighteen (18.37%) hospitals had set up FSMP counters for patients. Outpatients from 79 (80.61%) hospitals received FSMP in the department of clinical nutrition. Forty-five (45.92%) hospitals had charge codes. More than 20 different types of charges were collected. Conclusion: An FSMP clinical pathway prototype (Nutritional Screening-Assessment-Diagnosis-Treatment) has been implemented in China's tertiary medical institutions. However, many irregularities exist. A standardized clinical pathway with universality and enforceability needs to be developed and promoted. There is an urgent need for China to strengthen its regulation policies and for other countries to share their experiences in the clinical application of FSMP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.